Company Profile
HCW Biologics Stock Price, News & Analysis
- Ticker:
- HCWB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.41 USD (-0.58%)
Close
Last updated: August 6, 2026
12.8M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, HCWB closed down 0.58% at $3.41. No new same-company headline was identified in the current news window.
Company overview
Fusion Immunotherapy Company
HCW Biologics develops fusion immunotherapies for autoimmune disease, cancer, and age-related dysplasia. Its platform is based on the role of chronic inflammation across multiple disease areas.
HCW9302 Autoimmune Program
HCW9302 is an injectable, first-in-kind IL-2 fusion protein complex being developed for alopecia areata. It is designed to activate and expand regulatory T cells, thereby suppressing autoreactive immune cells that attack hair follicles.
Fusion Cytokine Platform
HCW’s platform combines immune-active proteins into engineered fusion complexes intended to shape specific immune-cell populations. The same design capabilities support programs in immune tolerance, oncology, and cell-therapy manufacturing.
Platform and Licensing Strategy
HCW combines internal development with business development and has licensed selected proprietary molecules to external partners. Data for HCW9206 as a reagent also suggest potential use in CAR T-cell manufacturing.
Future catalysts
Preliminary clinical data from the first two dose levels of the Phase 1 HCW9302 study in alopecia areata were expected in the first half of 2026.
A complete Phase 1 human data readout for HCW9302 is expected in the fourth quarter of 2026.
Recent news
- 01
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
Source: HCW Biologics
- 02
- 03
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Source: HCW Biologics
- 04
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Source: HCW Biologics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HCW Biologics (HCWB)?
HCW Biologics (HCWB) most recently closed at 3.41 USD, a -0.58% move versus the previous session.
What is the market cap of HCW Biologics (HCWB)?
HCW Biologics currently has a market capitalization of 12.8M USD on BioPharmSignal.
What does HCW Biologics do?
Fusion Immunotherapy Company HCW Biologics develops fusion immunotherapies for autoimmune disease, cancer, and age-related dysplasia. Its platform is based on the role of chronic inflammation across multiple disease areas. HCW9302 Autoimmune Program HCW9302 is an injectable, first-in-kind IL-2 fusion protein complex being developed for alopecia areata. It...
On which exchange is HCWB stock listed?
HCW Biologics (HCWB) is associated with NASDAQ, United States, Biopharma.
What is IL-2?
HCW9302 Autoimmune Program HCW9302 is an injectable, first-in-kind IL-2 fusion protein complex being developed for alopecia areata.
Which conditions is HCW Biologics targeting with IL-2?
HCW Biologics is associated with oncology, cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does HCW Biologics describe recent progress with IL-2?
Preliminary clinical data from the first two dose levels of the Phase 1 HCW9302 study in alopecia areata were expected in the first half of 2026. A complete Phase 1 human data readout for HCW9302 is expected in the fourth quarter of 2026.
What is Fusion?
Fusion Immunotherapy Company HCW Biologics develops fusion immunotherapies for autoimmune disease, cancer, and age-related dysplasia.